Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2011-08-16

Clinical Trial Update: Macugen Observational Study

View source ↗

Summary

Pfizer's Macugen (pegaptanib) observational study for age-related macular degeneration was terminated, with results posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Macugen (pegaptanib sodium)

Snippet

Sponsor: Pfizer | Conditions: Vascular Endothelial Growth Factor, Macular Degeneration | Status: TERMINATED | Results posted: 2011-08-16